2025
Diabetes Status and Long-Term Mortality and Major Amputation Outcomes Following Revascularization in Chronic Limb Threatening Ischemia
Callegari S, Romain G, Aggarwal A, Cleman J, Smolderen K, Mena-Hurtado C. Diabetes Status and Long-Term Mortality and Major Amputation Outcomes Following Revascularization in Chronic Limb Threatening Ischemia. Journal Of Vascular Surgery 2025 PMID: 40348290, DOI: 10.1016/j.jvs.2025.04.065.Peer-Reviewed Original ResearchChronic limb-threatening ischemiaLower-extremity bypassSub-hazard ratiosPeripheral vascular interventionsDM statusRisk of deathLimb-threatening ischemiaTeam-based careShared decision-makingCumulative incidenceDiabetes mellitusMedicare claims dataCumulative incidence of mortalityAll-cause mortalityType of revascularizationAmputation outcomesCare offerFine-Gray modelClaims dataCumulative incidence of deathLong-term mortalityMortality riskCox regression modelsHazard ratioDiabetes statusMedications for opioid use disorder in traditional medicare beneficiaries: associations with age
Ganz D, Lai J, Cantor J, Agniel D, Simon K, Stein B, Taylor E. Medications for opioid use disorder in traditional medicare beneficiaries: associations with age. Health Affairs Scholar 2025, 3: qxaf036. PMID: 40040649, PMCID: PMC11878533, DOI: 10.1093/haschl/qxaf036.Peer-Reviewed Original ResearchOpioid use disorderMOUD initiationIndex eventUse disorderTreat opioid use disorderAssociated with female sexRates of opioid use disorderIncreasing comorbidity scoreMultivariate logistic regressionAssociated with ageComorbidity scoreMedicare beneficiariesFemale sexOlder adultsAge-specific strategiesIncreased uptakeLogistic regressionOlder ageTraditional Medicare beneficiariesMOUDClaims dataMedication
2024
PEOPLE LIVING WITH DEMENTIA AND THEIR FAMILY MEMBERS INFORM A PERSON-CENTERED MEASURE OF “HOME TIME”
Boucher N, McKenna K, Seidenfeld J, Vick J, Burke J, Plassman B, Shepherd-Banigan M, Van Houtven C. PEOPLE LIVING WITH DEMENTIA AND THEIR FAMILY MEMBERS INFORM A PERSON-CENTERED MEASURE OF “HOME TIME”. Innovation In Aging 2024, 8: 206-206. PMCID: PMC11689051, DOI: 10.1093/geroni/igae098.0665.Peer-Reviewed Original ResearchQuality-of-lifeHealth facility settingsHealth settingsFacility settingPerson-centeredActivities of daily livingLow community involvementPerson-centered measuresFamily member informationApplied thematic analysisCommunity involvementSkilled nursingHealth facilitiesPLWDDaily livingMedication administrationSocial supportThematic analysisCare dutiesClaims dataHealthSpousesOutpatient surgeryDementiaHomeLong-Term Outcomes of Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Use Among Patients on Maintenance Dialysis
Pun P, Qin L, Minges K, Al-Khatib S, Friedman D. Long-Term Outcomes of Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Use Among Patients on Maintenance Dialysis. Heart Rhythm 2024 PMID: 39615818, DOI: 10.1016/j.hrthm.2024.11.050.Peer-Reviewed Original ResearchHospital admissionAccess interventionsAssociated with decreased riskFee-for-serviceLongitudinal cohort studyMedicare claims dataAssociated with decreased risk of deathImplantable cardioverter defibrillator useNational Cardiovascular Data Registry ICD RegistryBurden of cardiac diseaseRisk of deathDialysis access interventionsDefibrillator useClaims dataElevated risk of sudden cardiac deathImplantable cardioverter defibrillatorLong-term outcomesRisk of sudden cardiac deathStabilized inverse probabilityDialysis patientsElevated riskInclusion criteriaTV-ICDS-ICDICD RegistryRisk of Atherosclerotic Cardiovascular Disease Hospitalizations after Chronic Obstructive Pulmonary Disease Hospitalization among Older Adults.
Mosher C, Osazuwa-Peters O, Nanna M, MacIntyre N, Que L, Jones W, Palmer S, O'Brien E. Risk of Atherosclerotic Cardiovascular Disease Hospitalizations after Chronic Obstructive Pulmonary Disease Hospitalization among Older Adults. Annals Of The American Thoracic Society 2024, 21: 1516-1523. PMID: 39018486, PMCID: PMC11568506, DOI: 10.1513/annalsats.202401-017oc.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary disease hospitalizationsChronic obstructive pulmonary diseaseAtherosclerotic cardiovascular diseaseASCVD hospitalizationHospital outcomesMedicare beneficiariesCardiovascular diseaseHospitalization severityCardiovascular disease hospitalizationCardiovascular disease eventsRisk of cardiovascular diseaseAssociated with higher riskCox proportional hazards modelsPopulation of chronic obstructive pulmonary diseasePulmonary disease hospitalizationsHazard ratio estimatesRisk of atherosclerotic cardiovascular diseaseProportional hazards modelHospital 1 yearRetrospective cohort studyObstructive pulmonary diseaseOlder adultsClaims dataHospitalization riskHigh-risk subgroupsBy Any Other Name: Bowel Dysfunction After Proctectomy for Cancer and Its Predictive Factors in Administrative Databases
Leeds I, Coppersmith N, Moore M, Saleh A, Cruickshank K, Pantel H, Reddy V, Mongiu A. By Any Other Name: Bowel Dysfunction After Proctectomy for Cancer and Its Predictive Factors in Administrative Databases. Journal Of Surgical Research 2024, 303: 342-351. PMID: 39413695, DOI: 10.1016/j.jss.2024.09.027.Peer-Reviewed Original ResearchBowel dysfunctionRehabilitation proceduresPredictive factorsCosts of healthcare utilizationAssociated with bowel dysfunctionPopulation-based studyNeoadjuvant chemotherapy administrationLow anterior resection syndromeLow anterior resectionAdministrative claims dataRetrospective cohort studyAnterior resection syndromePostoperative bowel dysfunctionHealthcare utilizationPoisson regressionDiagnostic codesFollowed surgeryChemoradiation therapyFollow-up costsMultiagent chemotherapyStatistically significant covariatesAnterior resectionClaims dataCohort studyIndependent predictorsEvaluating the concordance between International Classification of Diseases, Tenth Revision Code and stroke severity as measured by the National Institutes of Health Stroke Scale
Taha M, Habib M, Lomachinsky V, Hadar P, Newhouse J, Schwamm L, Blacker D, Moura L. Evaluating the concordance between International Classification of Diseases, Tenth Revision Code and stroke severity as measured by the National Institutes of Health Stroke Scale. BMJ Neurology Open 2024, 6: e000831. PMID: 39363950, PMCID: PMC11448239, DOI: 10.1136/bmjno-2024-000831.Peer-Reviewed Original ResearchPaul Coverdell National Acute Stroke ProgramNational Institutes of Health Stroke ScaleInternational Classification of DiseasesClassification of DiseasesHealth Stroke ScaleInternational ClassificationICD-10Acute ischaemic strokeStroke severityICD-10 diagnosis codesStroke ScaleNIHSS scoreMeasures of stroke severityMedicare claims dataIntraclass correlation coefficientNational Institutes of Health Stroke Scale scoreNational InstituteMedicaid Services guidelinesService guidelinesStroke programClinical registryDiagnosis codesClaims dataSampled patientsExpert clinical evaluationUSPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years
Siddique S, Wang R, Yasin F, Gaddy J, Zhang L, Gross C, Ma X. USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years. JAMA Network Open 2024, 7: e2436358. PMID: 39361285, PMCID: PMC11450516, DOI: 10.1001/jamanetworkopen.2024.36358.Peer-Reviewed Original ResearchConceptsUS Preventive Services Task ForceUS Preventive Services Task Force recommendationsColorectal cancer screening uptakeAverage-risk individualsScreening uptakeHigher socioeconomic statusSocioeconomic statusScreening recommendationsColorectal cancerColorectal cancer screening recommendationsPreventive Services Task ForceCohort studyCancer screening recommendationsScreening uptake ratesInterrupted time series analysisLow socioeconomic statusPrivate insurance beneficiariesScreening ratesSocioeconomic disparitiesRetrospective cohort studyMain OutcomesPotential disparitiesEvaluate changesClaims dataAbsolute changeCost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy
Forman R, Long J, Westvold S, Agnish K, McManus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, 8: pkae067. PMID: 39133171, PMCID: PMC11376369, DOI: 10.1093/jncics/pkae067.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsOAA useAssociated with decreased adherenceRenal cell carcinomaAnticancer agentsDays of treatmentCombination therapyCell carcinomaStudy patientsInitial treatmentReal-world costsCombination groupImmunotherapyPatientsOOP costsTherapyTreatment typePercent daysPerspective of payersTreatmentClaims dataMedicare patientsAnalyzed differencesFee-for-service MedicarePharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease
Morales J, Gabriel N, Natarajan L, LaCroix A, Shadyab A, Xu R, Silverman J, Feldman H, Hernandez I, Aslanyan V, Bang A, Bevins E, Bowman G, Boyarko B, Chen X, Clelland C, Dodge H, Durant J, Edland S, Evans A, Galasko D, Gerwick W, Greenberg B, Herman M, Herold T, Hook V, Jacobs D, Kaye J, Kim D, Koo E, Kosik K, Léger G, Lupo J, Messer K, Momper J, Nygaard H, Pa J, Quinti L, Revta C, Rexach J, Rizzo S, Rynearson K, Schneider L, Slusher B, Tanzi R, Territo P, Yokoyama J. Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease. Alzheimer's & Dementia 2024, 20: 5236-5246. PMID: 39030734, PMCID: PMC11350022, DOI: 10.1002/alz.13872.Peer-Reviewed Original ResearchRisk of ADCross-sectional analysis of electronic health recordsAnalysis of electronic health recordsAD riskAssociated with risk of ADAssociated with AD riskAssociated with decreased prevalenceElectronic health recordsRetrospective cohort study designMedicare claims dataCohort study designCox proportional hazards regressionAssociated with riskCross-sectional analysisProportional hazards regressionPrevalence of ADMultiple sensitivity analysesAlzheimer's diseaseHealth recordsMedicare beneficiariesMedicare dataClaims dataStudy designHazards regressionPatient characteristicsIncorporating Medicare Advantage Admissions Into the CMS Hospital-Wide Readmission Measure
Kyanko K, Sahay K, Wang Y, Li S, Schreiber M, Hager M, Myers R, Johnson W, Zhang J, Krumholz H, Suter L, Triche E. Incorporating Medicare Advantage Admissions Into the CMS Hospital-Wide Readmission Measure. JAMA Network Open 2024, 7: e2414431. PMID: 38829614, PMCID: PMC11148674, DOI: 10.1001/jamanetworkopen.2024.14431.Peer-Reviewed Original ResearchConceptsCenters for Medicare & Medicaid ServicesSpecialty subgroupsPerformance quintileMedicare AdvantageReadmission ratesRisk-standardized readmission ratesHospital-wide readmission measureHospital outcome measuresTest-retest reliabilityRisk-adjustment variablesMeasurement reliabilityAdministrative claims dataReadmission measuresImprove measurement reliabilityIntegrated data repositoryMA beneficiariesQuintile rankingsMedicare beneficiariesMedicaid ServicesAll-causePublic reportingStudy assessed differencesClaims dataOutcome measuresMA cohortVariability in short-term mortality following repair of ruptured abdominal aortic aneurysms across centers and physicians
Romain G, Wang K, Scierka L, Cleman J, Callegari S, Aboian E, Smolderen K, Mena-Hurtado C. Variability in short-term mortality following repair of ruptured abdominal aortic aneurysms across centers and physicians. Journal Of Vascular Surgery 2024, 80: 737-745.e14. PMID: 38729585, DOI: 10.1016/j.jvs.2024.05.004.Peer-Reviewed Original ResearchPhysician variablesPhysician volumeRuptured infrarenal abdominal aortic aneurysmMortality riskPhysician levelAbdominal aortic aneurysmShort-term mortalityProcedure volumeMortality outcomesQuality of careAortic aneurysmMedian odds ratioShort-term mortality outcomesRepair of ruptured abdominal aortic aneurysmMedicare claims dataInfrarenal abdominal aortic aneurysmRuptured abdominal aortic aneurysmVascular Quality Initiative databaseAssociated with short-term mortalityLogistic regression modelsMortality rateCenter-level factorsCare managementClaims dataOdds ratio
2023
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
Kopel H, Nguyen V, Boileau C, Bogdanov A, Winer I, Ducruet T, Zeng N, Bonafede M, Esposito D, Martin D, Rosen A, Van de Velde N, Vermund S, Gravenstein S, Mansi J. Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults. Vaccines 2023, 11: 1711. PMID: 38006043, PMCID: PMC10675676, DOI: 10.3390/vaccines11111711.Peer-Reviewed Original ResearchCOVID-19-related hospitalizationRelative vaccine effectivenessOutpatient visitsPrimary care electronic health recordsCOVID-19-related outcomesVaccine-induced protectionMedical claims dataCOVID-19 vaccineSARS-CoV-2Electronic health recordsVaccine effectivenessVaccine recipientsMRNA vaccinesBivalent vaccineBaseline differencesStudy populationClaims dataOmicron variantComparative effectivenessHospitalizationPropensity scoreVaccineOlder adultsHealth recordsVisitsAssociation Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study
Faridi K, Strom J, Kundi H, Butala N, Curtis J, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky E, Yeh R. Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study. Journal Of The American Heart Association 2023, 12: e029588. PMID: 37449567, PMCID: PMC10382113, DOI: 10.1161/jaha.123.029588.Peer-Reviewed Original ResearchConceptsExtended duration dual antiplatelet therapyDuration dual antiplatelet therapyNet adverse clinical eventsDual antiplatelet therapyAdverse clinical eventsPercutaneous coronary interventionCoronary interventionClinical eventsNonfrail patientsAntiplatelet therapyFrail patientsClaims dataMonths of DAPTClaims-based indexYears of ageMajor bleedingCause mortalityMultivariable adjustmentOlder patientsDAPT studyResults PatientsBackground FrailtyMyocardial infarctionClinical trialsMedicare claimsAccuracy of administrative claims prescription fill data to estimate glucocorticoid use and dose in patients with rheumatoid arthritis
Galvao R, Curtis J, Harrold L, Wu Q, Xie F, George M. Accuracy of administrative claims prescription fill data to estimate glucocorticoid use and dose in patients with rheumatoid arthritis. Pharmacoepidemiology And Drug Safety 2023, 32: 1271-1279. PMID: 37345649, PMCID: PMC10543479, DOI: 10.1002/pds.5660.Peer-Reviewed Original ResearchConceptsGlucocorticoid usePrescription fillsExposure misclassificationRheumatoid arthritisInfection riskRisk estimatesAdjusted risk ratioPhysician-reported measuresDeterministic sensitivity analysesRisk ratioMedicare studyRegistry dataClaims dataAverage doseNPV 93.6Sensitivity 88.1DoseArthritisPatientsPrescriptionRiskDosesSame periodPrior studiesMisclassificationLongitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014
Sankar A, Everhart A, Jena A, Jeffery M, Ross J, Shah N, Karaca-Mandic P. Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014. The Joint Commission Journal On Quality And Patient Safety 2023, 49: 458-466. PMID: 37380503, DOI: 10.1016/j.jcjq.2023.05.003.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseFDA safety communicationPhysician characteristicsLabel prescribingCare physiciansTestosterone prescribingService administrative claims dataNon-primary care physiciansCertain physician characteristicsDrug Administration (FDA) safety communicationPrimary care physiciansAdministrative claims dataCase mix indexTestosterone therapyArtery diseaseTestosterone prescriptionsPrescribing levelsMean agePrescription trendsTeaching hospitalClaims dataPrescription levelsMedicare feePrescribingUS FoodFrequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States
Naidu S, Sutton M, Gao W, Fine J, Xie J, Desai N, Owens A. Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States. Journal Of Medical Economics 2023, 26: 682-690. PMID: 37170479, DOI: 10.1080/13696998.2023.2208966.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyDefinitive diagnosisHypertrophic cardiomyopathyHCM diagnosisMedicare Supplemental databasesIBM MarketScan CommercialEmergency room visitsAdministrative claims dataMisclassification of patientsEligible patientsMarketScan CommercialMost patientsRoom visitsAlternative diagnosesPotential misdiagnosesCardiovascular conditionsInappropriate treatmentDatabase studyClaims dataHealthcare costsDiagnostic journeyPatientsEconomic burdenCurrent studyDiagnostic historyTrends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016.
Grada A, Armstrong A, Bunick C, Salem R, Feldman S. Trends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016. Journal Of Drugs In Dermatology 2023, 22: 265-270. PMID: 36877883, DOI: 10.36849/jdd.7345.Peer-Reviewed Original ResearchConceptsOral antibiotic useOral antibioticsAntibiotic useAntibiotic treatmentAcne treatmentHealth care claims dataOral antibiotic treatmentShort study durationIBM MarketScanPrimary outcomeGuideline recommendationsRetrospective studyAcne vulgarisRetrospective analysisClaims dataJ DrugsPatientsStudy durationAmerican AcademyTherapeutic classesSeparate occasionsDay gapMonthsAntibiotic resistanceAntibioticsEvaluation of High-Deductible Health Plans and Acute Glycemic Complications Among Adults With Diabetes
Jiang D, Herrin J, Van Houten H, McCoy R. Evaluation of High-Deductible Health Plans and Acute Glycemic Complications Among Adults With Diabetes. JAMA Network Open 2023, 6: e2250602. PMID: 36662531, PMCID: PMC9860518, DOI: 10.1001/jamanetworkopen.2022.50602.Peer-Reviewed Original ResearchConceptsHigh-deductible health plansSevere hypoglycemiaED visitsHealth plansCohort studyHDHP enrollmentPotential treatment selection biasAcute diabetes complicationsGlucose-lowering medicationsRetrospective cohort studyOptimal diabetes careAdministrative claims dataTreatment selection biasMixed effects logistic regression modelsLogistic regression modelsGlycemic complicationsGlycemic controlPatient ageDiabetes complicationsDiabetes careHospital visitsStudy populationInverse propensity scoreMAIN OUTCOMEClaims data
2022
Habitual sleep duration and its relationship with cardiovascular health, healthcare costs, and resource utilization in a working population
Aneni E, Osondu C, Joseph J, Saeed G, Valero-Elizondo J, Veledar E, Nasir K. Habitual sleep duration and its relationship with cardiovascular health, healthcare costs, and resource utilization in a working population. Sleep Health 2022, 9: 77-85. PMID: 36371382, PMCID: PMC9991949, DOI: 10.1016/j.sleh.2022.10.001.Peer-Reviewed Original ResearchConceptsCardiovascular healthHabitual sleep durationSleep durationHealthcare expendituresHealthcare costsOptimal cardiovascular healthIdeal cardiovascular healthBaptist Health South FloridaHealthcare resource utilizationBody mass indexBetter cardiovascular healthMedical claims dataHours of sleepLower healthcare expendituresCVH metricsMore hoursBlood pressureMass indexMean ageEmergency roomCardiovascular diseaseHigher oddsHispanic ethnicityPhysical activityClaims data
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply